ReviewMediators of inflammation2012
Cyclooxygenase inhibition in sepsis: is there life after death?
Review in Mediators of inflammation, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
25 citing papers in PubMed, 1 synthesis or guideline pooled it, 42 citations in OpenAlex.
- Effect of Antiplatelet Therapy on Acute Respiratory Distress Syndrome and Mortality in Critically Ill Patients: A Meta-Analysis.PloS one · 2016Pooled it
- Non-apoptotic Regulated Cell Death Mechanisms in Sepsis and their Therapeutic Potential.Inflammation · 2026Review
- Multi-Omics and Network-Based Drug Repurposing for Septic Cardiomyopathy.Pharmaceuticals (Basel, Switzerland) · 2025Article
- Metamizole outperforms meloxicam in sepsis: insights on analgesics, survival and immunomodulation in the peritoneal contamination and infection sepsis model.Frontiers in immunology · 2024Article
- Protectin DX promotes the inflammatory resolution via activating COX-2/L-PGDS-PGDInternational immunopharmacology · 2022Article
- A Novel Role for Cytochrome P450 Epoxygenase Metabolites in Septic Shock.Critical care explorations · 2022Article
- Past Experiences for Future Applications of Metabolomics in Critically Ill Patients with Sepsis and Septic Shocks.Metabolites · 2021Review
- Lipopolysaccharide-Induced Nitric Oxide and Prostaglandin E2 Production Is Inhibited by Tellimagrandin II in Mouse and Human Macrophages.Life (Basel, Switzerland) · 2021Article
- Article
- Paeoniflorin and Hydroxysafflor Yellow A in Xuebijing Injection Attenuate Sepsis-Induced Cardiac Dysfunction and Inhibit Proinflammatory Cytokine Production.Frontiers in pharmacology · 2020Article
- A Review of Malaysian Herbal Plants and Their Active Constituents with Potential Therapeutic Applications in Sepsis.Evidence-based complementary and alternative medicine : eCAM · 2020Review
- Volatile anesthetics isoflurane and sevoflurane directly target and attenuate Toll-like receptor 4 system.FASEB journal : official publication of the Federation of American Societies for Experimental Biology · 2019Article
- Protective effect of isoliquiritigenin against cerebral injury in septic mice via attenuation of NF-κB.Inflammopharmacology · 2019Article
- Decidual stromal cell-derived PGEAmerican journal of reproductive immunology (New York, N.Y. : 1989) · 2018Article
- Catecholamines for inflammatory shock: a Jekyll-and-Hyde conundrum.Intensive care medicine · 2016Review
- Nitric oxide-mediated vascular function in sepsis using passive leg movement as a novel assessment: a cross-sectional study.Journal of applied physiology (Bethesda, Md. : 1985) · 2016Article
- Prostaglandin E₂ constrains systemic inflammation through an innate lymphoid cell-IL-22 axis.Science (New York, N.Y.) · 2016Article
- Perinatal Endotoxemia Induces Sustained Hepatic COX-2 Expression through an NFκB-Dependent Mechanism.Journal of innate immunity · 2016Article
- Association of prior antiplatelet agents with mortality in sepsis patients: a nationwide population-based cohort study.Intensive care medicine · 2015Article
- Therapeutical Administration of Peptide Pep19-2.5 and Ibuprofen Reduces Inflammation and Prevents Lethal Sepsis.PloS one · 2015Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
Abstract
Prostaglandins are important mediators and modulators of the inflammatory response to infection. The prostaglandins participate in the pathogenesis of hemodynamic collapse, organ failure, and overwhelming inflammation that characterize severe sepsis and shock. In light of this, cyclooxygenase (COX) inhibiting pharmacological agents have been extensively studied for their capacity to ameliorate the aberrant physiological and immune responses during severe sepsis. Animal models of sepsis, using the systemic administration of pathogen-associated molecular patterns (PAMPs) or live pathogens, have been used to examine the effectiveness of COX inhibition as a treatment for severe sepsis. These studies have largely shown beneficial effects on mortality. However, human studies have failed to show clinical utility of COX inhibitor treatment in severely septic patients. Why this approach "worked" in animals but not in humans might reflect differences in the controlled nature of animal investigations compared to human studies. This paper contrasts the impact of COX inhibitors on mortality in animal models of sepsis and human studies of sepsis and examines potential reasons for differences between these two settings.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.